title: Minimally invasive surgery plus recombinant tissue-type plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema.
abstract: OBJECTIVE
  Perihematomal edema (PHE) can worsen outcomes after intracerebral hemorrhage (ICH). Reports suggest that blood degradation products lead to PHE. We hypothesized that hematoma evacuation will reduce PHE volume and that treatment with recombinant tissue-type plasminogen activator (rt-PA) will not exacerbate it.
  
  
  METHODS
  Minimally invasive surgery and rt-PA in ICH evacuation (MISTIE) phase II tested safety and efficacy of hematoma evacuation after ICH. We conducted a semiautomated, computerized volumetric analysis on computed tomography to assess impact of hematoma removal on PHE and effects of rt-PA on PHE. Volumetric analyses were performed on baseline stability and end of treatment scans.
  
  
  RESULTS
  Seventy-nine surgical and 39 medical patients from minimally invasive surgery and rt-PA in ICH evacuation phase II (MISTIE II) were analyzed. Mean hematoma volume at end of treatment was 19.6±14.5 cm(3) for the surgical cohort and 40.7±13.9 cm(3) for the medical cohort (P<0.001). Edema volume at end of treatment was lower for the surgical cohort: 27.7±13.3 cm(3) than medical cohort: 41.7±14.6 cm(3) (P<0.001). Graded effect of clot removal on PHE was observed when patients with >65%, 20% to 65%, and <20% ICH removed were analyzed (P<0.001). Positive correlation between PHE reduction and percent of ICH removed was identified (ρ=0.658; P<0.001). In the surgical cohort, 69 patients underwent surgical aspiration and rt-PA, whereas 10 underwent surgical aspiration only. Both cohorts achieved similar clot reduction: surgical aspiration and rt-PA, 18.9±14.5 cm(3); and surgical aspiration only, 24.5±14.0 cm(3) (P=0.26). Edema at end of treatment in surgical aspiration and rt-PA was 28.1±13.8 cm(3) and 24.4±8.6 cm(3) in surgical aspiration only (P=0.41).
  
  
  CONCLUSIONS
  Hematoma evacuation is associated with significant reduction in PHE. Furthermore, PHE does not seem to be exacerbated by rt-PA, making such neurotoxic effects unlikely when the drug is delivered to intracranial clot.
authors: The Johns Hopkins Hospital, Baltimore, MD, USA.
authors: W Andrew
authors: WA
authors: Mould
authors: J Ricardo
authors: JR
authors: Carhuapoma
authors: John
authors: J
authors: Muschelli
authors: Karen
authors: K
authors: Lane
authors: Timothy C
authors: TC
authors: Morgan
authors: Nichol A
authors: NA
authors: McBee
authors: Amanda J
authors: AJ
authors: Bistran-Hall
authors: Natalie L
authors: NL
authors: Ullman
authors: Paul
authors: P
authors: Vespa
authors: Neil A
authors: NA
authors: Martin
authors: Issam
authors: I
authors: Awad
authors: Mario
authors: M
authors: Zuccarello
authors: Daniel F
authors: DF
authors: Hanley
mesh_terms: D000368:Aged; D001929:Brain Edema / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control*; D002543:Cerebral Hemorrhage / Q000628:therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006406:Hematoma / Q000150:complications* / Q000000981:diagnostic imaging; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D013396:Suction / Q000379:methods; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator
references: Nat Med. 1998 Feb;4(2):228-31
references: 9461198
references: Stroke. 2002 Nov;33(11):2631-5
references: 12411653
references: Neurocrit Care. 2005;3(3):237-45
references: 16377836
references: J Neurosurg. 1994 Jul;81(1):93-102
references: 8207532
references: Neurosurgery. 2010 Apr;66(4):648-55
references: 20305489
references: Neurosurgery. 1986 Oct;19(4):553-72
references: 3491340
references: Cochrane Database Syst Rev. 2008 Oct 08;(4):CD000200
references: 18843607
references: Neurol Res. 2003 Apr;25(3):254-62
references: 12739233
references: J Neurosurg. 1986 Nov;65(5):697-703
references: 3772459
references: J Neurosurg. 1987 Apr;66(4):568-76
references: 3559723
references: Neurosurgery. 1986 Oct;19(4):540-6
references: 3491338
references: Curr Eye Res. 2005 Apr;30(4):291-7
references: 16020259
references: Stroke. 2004 Feb;35(2):354-6
references: 14757877
references: Stroke. 2000 Mar;31(3):726-32
references: 10700511
references: Stroke. 1998 Sep;29(9):1791-8
references: 9731596
references: Neurocrit Care. 2005;2(1):23-7
references: 16174964
references: FASEB J. 2005 Aug;19(10):1280-9
references: 16051695
references: J Neurosurg Anesthesiol. 2003 Jul;15(3):230-3
references: 12826970
references: Stroke. 2000 Mar;31(3):596-600
references: 10700491
references: Neurocrit Care. 2011 Feb;14(1):118-26
references: 21161434
references: J Neurol. 2011 Apr;258(4):661-9
references: 21340523
references: Exp Neurol. 2001 Feb;167(2):341-7
references: 11161622
references: Neurocrit Care. 2007;6(1):22-9
references: 17356187
references: J Neurosurg. 2011 Sep;115(3):592-601
references: 21663412
references: Neurology. 2001 Nov 13;57(9):1611-7
references: 11706101
references: Stroke. 2011 Sep;42(9):2625-9
references: 21737803
references: Neurosurgery. 1988 Oct;23(4):439-44
references: 3200374
references: J Neurosurg. 2001 Oct;95(4):680-6
references: 11596963
references: Acta Neurochir Suppl. 2005;95:389-92
references: 16463887
references: Stroke. 2010 Sep;41(9):2108-29
references: 20651276
references: AJNR Am J Neuroradiol. 2002 Sep;23(8):1322-6
references: 12223372
references: Nature. 1996 Nov 14;384(6605):123-4
references: 8906786
references: J Cereb Blood Flow Metab. 2001 Jul;21(7):804-10
references: 11435792
references: J Neuropathol Exp Neurol. 1988 Mar;47(2):128-37
references: 3339371
references: J Cell Biol. 2000 May 29;149(5):1157-66
references: 10831618
references: Stroke. 2002 Nov;33(11):2636-41
references: 12411654
references: BMC Neurol. 2011 Jun 23;11:76
references: 21699716
references: Lancet. 2005 Jan 29-Feb 4;365(9457):387-97
references: 15680453
references: Stroke. 2011 Jan;42(1):73-80
references: 21164136
references: Surg Neurol. 1988 Feb;29(2):101-7
references: 3336844
references: Stroke. 2010 Nov;41(11):2681-3
references: 20947849
references: Stroke. 2013 Jun;44(6 Suppl 1):S74-8
references: 23709738
references: Am J Ophthalmol. 1991 Feb 15;111(2):197-204
references: 1899537
references: Ophthalmology. 2003 Apr;110(4):704-8
references: 12689889
references: Neuroradiology. 2013 Feb;55(2):145-56
references: 22987060
references: Neurocrit Care. 2008;8(3):322-9
references: 18327659
references: J Neurosurg. 1999 Mar;90(3):491-8
references: 10067918
references: Eur J Neurol. 2011 Nov;18(11):1323-8
references: 21457176
references: Neurosurgery. 1990 Nov;27(5):674-82; discussion 682
references: 2259395
references: Stroke. 1999 Jun;30(6):1167-73
references: 10356094
references: Curr Opin Crit Care. 2007 Apr;13(2):169-74
references: 17327738
references: Neurology. 2009 Dec 8;73(23):1963-8
references: 19996072
references: Neurocrit Care. 2005;2(3):274-81
references: 16159075
references: Ann Neurol. 1982 Mar;11(3):266-71
references: 7092179
references: Neurosurgery. 1986 Oct;19(4):547-52
references: 3491339
references: Acta Neurochir Suppl. 2008;105:147-51
references: 19066101